Anti‐angiogenic therapy for lung cancer
Información
- DOI:
- https://doi.org/10.1002/14651858.CD008047Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 octubre 2009see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer de pulmón
- Copyright:
-
- Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
The senior and supervising reviewer is NP. He and MK will be involved in study selection, quality appraisal, data analysis and results discussion. Each of the other reviewers will be involved in selected quality appraisal and data extraction under specific subheadings listed in "types of interventions". All authors will be involved in assessment of the final review.
Declarations of interest
Dr Nick Pavlakis has served on Lung Advisory Boards for Amgen, Roche, Pfizer and Astra Zeneca; he has received speaking honoraria from Roche; he has received travel grants from Roche and Amgen.
Dr Chris Lee has received research Grant support from Astra Zeneca and served on Advisory Boards for Astra Zeneca and Bristol Myers Squibb.
Dr Gavin Marx has received Grant in Aid support from Progen Industries and Sanofi Aventis, and served on Advisory Boards for Astra Zeneca and Amgen. He has also received a speakers fee from Sanofi Aventis.
Dr Shane White has served on Advisory Boards for Astra Zeneca and Roche and received travel grants from Roche, Amgen and Astra Zeneca.
Dr Mustafa Khasraw has received travel grant and research funding support from Merck.
Acknowledgements
The Cochrane Lung Group is acknowledged for its valuable assistance.
Version history
| Published | Title | Stage | Authors | Version |
| 2009 Oct 07 | Anti‐angiogenic therapy for lung cancer | Protocol | Nick Pavlakis, Gavin Marx, Shane White, Christopher W Lee, Mustafa Khasraw | |
